EMERYVILLE, Calif.--(BUSINESS WIRE)--Amyris, Inc. (NASDAQ:AMRS), which applies its industrial synthetic biology platform to provide renewable alternatives to select petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide, today announced financial results for the first quarter ended March 31, 2011.
Total revenues for the first quarter ended March 31, 2011 were $37.2 million versus $29.7 million in the prior quarter with Cost of Products Sold of $34.4 million versus $27.5 million. Research and Development expense increased to $19.7 million from $17.0 million and Sales, General and Administrative expense increased to $16.0 million from $11.0 million. First quarter GAAP net loss attributable to common stockholders was $33.1 million, compared with $25.6 million in the prior quarter. On a non-GAAP basis, the net loss attributable to Amyris, Inc. common stockholders was $29.1 million for the quarter, compared to $22.1 million in the prior quarter. A reconciliation of GAAP to non-GAAP results is included below.
The company’s balance of cash, cash equivalents and marketable securities was $227.2 million at the end of the first quarter versus $257.9 million at the end of the prior quarter.
“We continue to meet our critical milestones, including delivering our first renewable product to customers and completing our first commercial production facility,” said John Melo, CEO of Amyris. “These achievements clearly communicate that we have become a commercial operation, and our focus as a company is to ramp up our operations quickly to meet customer demand and deliver a growing portfolio of high-value, renewable products.”
Highlights of recent accomplishments include:
- Delivery of first Amyris renewable product, No Compromise® squalane, to first customer;
- Completion of first commercial production facility, located in Piracicaba, São Paulo, Brazil at a facility owned by Biomin do Brasil Nutriҫão Animal Ltda. in Brazil; and
- Secured additional production capacity for manufacture of Amyris’s Biofene™ through agreements with Paraíso Bioenergia S.A. and Antibióticos S.A.
Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of hydrocarbon molecules — flexible building blocks which can be used in a wide range of products. Amyris is commercializing these products both as No Compromise renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil S.A., a subsidiary of Amyris, oversees the establishment and expansion of Amyris’s production in Brazil. Amyris also has fuel distribution capabilities in the United States through its subsidiary, Amyris Fuels, LLC. More information about Amyris is available at www.amyris.com.
Conference Call Information
The company will discuss these results in a conference call scheduled for today at 2:00 p.m. PDT/5:00 p.m. EDT. Investors may access a live audio webcast of this conference call and the earnings call presentation in the Investor section of the Company’s website at http://investors.amyris.com. An audio replay of the conference call will be available approximately two hours after the conclusion of the call and can be accessed by dialing 888-203-1112 if calling from within the United States or 719-457-0820 if calling from outside the United States and entering the replay pass code 8390106. A replay of the webcast will be available on the Investor Relations section of the Company’s website approximately two hours after the conclusion of the call and remain available for approximately 60 calendar days.
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as statements regarding ramping up production, customer demand for and value of our anticipated products and product sales) that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays in production and commercialization of products and other risks detailed in the “Risk Factors” section of Amyris’s Form 10-K, as filed on March 14, 2011 pursuant to Rule 424(b) under the Securities Act of 1933. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events or otherwise.
Non-GAAP Financial Information
Consolidated financial information has been presented in accordance with GAAP as well as on a non-GAAP basis. On a non-GAAP basis, financial measures exclude non-cash items such as stock-based compensation. Management believes that it is useful to supplement its GAAP financial statements with this non-GAAP information because management uses such information internally for its operating, budgeting and financial planning purposes. These non-GAAP financial measures also facilitate management’s internal comparisons to Amyris’s historical performance as well as comparisons to the operating results of other companies. In addition, Amyris believes these non-GAAP financial measures are useful to investors because they allow for greater transparency into the indicators used by management as a basis for its financial and operational decision-making. Non-GAAP information is not prepared under a comprehensive set of accounting rules and therefore should only be read in conjunction with financial information reported under U.S. GAAP when understanding Amyris’s operating performance. A reconciliation between GAAP and non-GAAP financial information is provided in the financial statement tables below.
Amyris, the Amyris logo, Biofene and No Compromise are trademarks or registered trademarks of Amyris, Inc.
|Condensed Consolidated Statement of Operations|
|(In thousands, except share and per share amounts)|
Three Months Ended
|Grants and collaboration revenue||3,154||3,701|
|Cost and operating expenses|
|Cost of product sales||34,382||10,003|
|Research and development (1)||19,736||11,178|
|Sales, general and administrative (1)||15,978||9,216|
|Total cost and operating expenses||70,096||30,397|
|Loss from operations||(32,922||)||(16,742||)|
|Other income (expense):|
|Other income, net||51||515|
|Total other income (expense)||(225||)||407|
|Loss attributable to noncontrolling interest||10||183|
|Net loss attributable to Amyris, Inc. common stockholders||$||(33,137||)||$||(16,152||)|
Net loss per share attributable to common stockholders basic and diluted
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic and diluted
|(1)||Includes stock-based compensation expense of the following for the periods presented:|
|Research and development||$||977||$||453|
|Sales, general and administrative||3,030||1,346|
|Total stock-based compensation expense||$||4,007||$||1,799|
|Condensed Consolidated Balance Sheets|
|Cash, cash equivalents and marketable securities||$||227,176||$||257,933|
|Prepaid expenses and other current assets||5,649||2,905|
|Total current assets||246,966||270,059|
|Property and equipment, net||74,065||54,847|
|Liabilities and Equity|
|Accrued and other current liabilities||19,698||14,795|
|Capital lease obligation, current portion||2,937||2,854|
|Debt, current portion||1,562||1,911|
|Total current liabilities||43,086||27,241|
|Capital lease obligation, net of current portion||2,325||3,091|
|Long-term debt, net of current portion||9,754||4,734|
|Deferred rent, net of current portion||10,935||11,186|
|Deferred revenue, net of current portion||988||1,130|
|Amyris, Inc. stockholders’ equity||280,466||307,546|
|Total liabilities and equity||$||350,434||$||357,453|
|Supplemental Consolidated Financial Information|
|(In thousands, except per share amounts)|
Three Months Ended
|Other Selected Financial Information:|
|Depreciation and amortization||$||2,105||$||1,625|
|Reconciliation of GAAP to Non-GAAP Net Loss Per Share:|
Net loss attributable to Amyris, Inc., common stockholders (GAAP)
|Stock Compensation Expense||4,007||1,799|
Net loss attributable to Amyris, Inc., common stockholders (Non- GAAP)
Net loss per share attributed to common stockholders basic and diluted (GAAP)
|Stock Compensation Expense||0.10||0.36|
Net loss per share attributed to common stockholders basic and diluted (Non-GAAP)